Ekovolt Welcomes Éric Scotto, Co-Founder of Akuo Energy, as a Shareholder, and Rebrands as Pont Digital Infrastructure Business Wire Ekovolt, a holding company focused on the development and investment in next-generation data centre infrastructure, and co-owner of Voltekko, a Southern European data centre development platform, today announces two milestones: Éric Scotto — co-founder and former President of Akuo Energy, a pioneering figure in the French and international energy transition — becoming a shareholder, and [...]
Manago AI, Formerly SALESmanago, Unveils New Identity and Agentic AI Capabilities to Help Brands Move Faster and Make Powerful Marketing Feel Simple Business Wire - Manago AI helps brands understand every customer and turn insights into personalised engagement in minutes, dramatically reducing marketing complexity
Everforth Launches New Era as Rebrand Elevates Technology and Digital Engineering Capabilities at Scale Business Wire Now trading under NYSE ticker EFOR
HW International Rebrands as Dubois, Uniting Its Business Under One Global Name April 16, 2026 HW International has rebranded to Dubois, bringing its European and Australian operations together under a single global identity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415999888/en/ In Australia, this includes a company name change from HW Wood Australia Pty Ltd to Dubois Insurance Pty Ltd, completing the group’s transition to a single [...]
Thermochemical Energy Storage Leader Redoxblox Rebrands as Tempo March 31, 2026 Breaking the heat barrier: Tempo advances towards commercial rollout of continuously delivered electrified industrial heat at up to 1,200°C
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq January 5, 2026 Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.
